In Another Blow For HDL Therapies, Cerenis’ CER-001 Stumbles In Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Intravenous HDL mimetic candidate CER-001 misses endpoint for regression of plaque in Phase IIb study, but Cerenis indicates it’s still committed to the therapy.